We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

1 hedge funds and large institutions have $425K invested in Revance Therapeutics, Inc. in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 170 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 173 → 1 (-172)

100% less capital invested

Capital invested by funds: $249M → $425K (-$249M)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 170

Holders
1
Holders Change
-172
Holders Change %
-99.42%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
170
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$26.1M
2
BCM
Beryl Capital Management
California
-$18M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$17.1M
4
OBAM
ODDO BHF Asset Management
France
-$15.5M
5
Fidelity International
Fidelity International
Bermuda
-$12.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCIA
26
Gabelli & Co Investment Advisers
New York
– -$3.22M -1,058,500 Closed
Northern Trust
27
Northern Trust
Illinois
– -$3.01M -991,043 Closed
Morgan Stanley
28
Morgan Stanley
New York
– -$2.72M -893,686 Closed
Goldman Sachs
29
Goldman Sachs
New York
– -$2.47M -812,927 Closed
Charles Schwab
30
Charles Schwab
California
– -$2.42M -797,299 Closed
WIC
31
Water Island Capital
New York
– -$2.2M -722,234 Closed
RHJA
32
Rice Hall James & Associates
California
– -$2.06M -678,541 Closed
SC
33
Slotnik Capital
Texas
– -$2.04M -671,607 Closed
SFI
34
Susquehanna Fundamental Investments
Pennsylvania
– -$1.68M -551,224 Closed
FIA
35
FNY Investment Advisers
New York
– -$1.45M -477,823 Closed
EWM
36
Essex Woodlands Management
Texas
– -$1.39M -457,085 Closed
Man Group
37
Man Group
United Kingdom
– -$1.35M -443,544 Closed
N
38
Nuveen
North Carolina
– -$1.29M -423,189 Closed
Hudson Bay Capital Management
39
Hudson Bay Capital Management
Connecticut
– -$1.26M -414,310 Closed
Wellington Management Group
40
Wellington Management Group
Massachusetts
– -$1.25M -411,523 Closed
Barclays
41
Barclays
United Kingdom
– -$1.22M -402,691 Closed
NPT
42
National Philanthropic Trust
Pennsylvania
– -$1.06M -350,000 Closed
VAM
43
Vazirani Asset Management
New York
– -$1.06M -350,000 Closed
LP
44
LMR Partners
United Kingdom
– -$1.06M -347,207 Closed
Bank of New York Mellon
45
Bank of New York Mellon
New York
– -$936K -307,764 Closed
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
– -$921K -303,073 Closed
CS
47
Candriam SCA
Luxembourg
– -$909K -299,039 Closed
ECM
48
ExodusPoint Capital Management
New York
– -$904K -297,458 Closed
NYLIM
49
New York Life Investment Management
New York
– -$899K -295,670 Closed
CSS
50
Cubist Systematic Strategies
Connecticut
– -$893K -293,675 Closed
1
2
3 4 5

RVNC Hedge Fund Activity: Q1 2025 in Review

1 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2025, worth a combined $425K — down 100% from $249M a quarter earlier.

Sellers outnumbered buyers: 170 funds closed out of RVNC and 0 opened new positions — a net loss of 170 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $26.1M sold.

  • 1 institutional investor held Revance Therapeutics, Inc. (RVNC) as of Q1 2025, down from 173 in Q4 2024.
  • Funds reported $425K of Revance Therapeutics, Inc. stock for Q1 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Revance Therapeutics, Inc. positions in Q1 2025 and 170 closed out, a net change of -170 holders.
  • The largest Revance Therapeutics, Inc. seller in Q1 2025 was BlackRock, an estimated $26.1M sold.

Based on aggregated 13F filings for Q1 2025.